Circulating microRNA-21 as a novel biomarker for hepatocellular carcinoma
Background & Aims Several groups have reported the significance of circulating microRNA as a biochemical marker of cancer. To our knowledge, however, there are no reports on the significance of circulating microRNA in hepatocellular carcinoma. The aim of this study was to evaluate the significan...
Gespeichert in:
| Veröffentlicht in: | Journal of hepatology 2012-01, Vol.56 (1), p.167-175 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 175 |
|---|---|
| container_issue | 1 |
| container_start_page | 167 |
| container_title | Journal of hepatology |
| container_volume | 56 |
| creator | Tomimaru, Yoshito Eguchi, Hidetoshi Nagano, Hiroaki Wada, Hiroshi Kobayashi, Shogo Marubashi, Shigeru Tanemura, Masahiro Tomokuni, Akira Takemasa, Ichiro Umeshita, Koji Kanto, Tatsuya Doki, Yuichiro Mori, Masaki |
| description | Background & Aims Several groups have reported the significance of circulating microRNA as a biochemical marker of cancer. To our knowledge, however, there are no reports on the significance of circulating microRNA in hepatocellular carcinoma. The aim of this study was to evaluate the significance of plasma microRNA-21 level as a biochemical marker for hepatocellular carcinoma. Methods Plasma microRNA-21 level was measured by qRT-PCR in 10 patients before and after curative resection of hepatocellular carcinoma. Plasma microRNA-21 was also compared in other groups of: 126 patients with hepatocellular carcinoma, 30 patients with chronic hepatitis, and 50 healthy volunteers. The power of microRNA-21 in differentiating hepatocellular carcinoma from chronic hepatitis or from healthy volunteers was compared to that of α-fetoprotein. Results In the 10-patient group, plasma microRNA-21 levels significantly diminished after surgery compared with the pre-operative values ( p = 0.0125). Plasma microRNA-21 level in the 126 patients with hepatocellular carcinoma was significantly higher than in patients with chronic hepatitis and healthy volunteers ( p < 0.0001 , p < 0.0001, respectively). ROC analysis of plasma microRNA-21 yielded an AUC of 0.773 with 61.1% sensitivity and 83.3% specificity when differentiating hepatocellular carcinoma from chronic hepatitis, and an AUC of 0.953 with 87.3% sensitivity and 92.0% specificity when differentiating hepatocellular carcinoma from healthy volunteers. Both sets of values were superior to α-fetoprotein and improved for the combination of microRNA-21 and α-fetoprotein. Conclusions Plasma microRNA-21 level is a promising biochemical marker for hepatocellular carcinoma. |
| doi_str_mv | 10.1016/j.jhep.2011.04.026 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_911951791</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0168827811005216</els_id><sourcerecordid>911951791</sourcerecordid><originalsourceid>FETCH-LOGICAL-c506t-b451308b43095638a4c85daaf8b399f1196e9f20323a821b3cc130f4a32d61af3</originalsourceid><addsrcrecordid>eNp9kU1v1DAQhi0EotvCH-CAckE9JczYjteWEFK1olCpAomPs-U4NjjNxoudVOq_x9EuIHHgNJfnnY9nCHmB0CCgeD00ww93aCggNsAboOIR2aAAqEFwfEw2BZK1pFt5Rs5zHgCAgeJPyRnFLVeSiw252YVkl9HMYfpe7YNN8fPHq5piZXJlqineu7HqQtybdOdS5WOqykgzR-vGscRSZU2yYSrAM_LEmzG756d6Qb5dv_u6-1Dffnp_s7u6rW0LYq473iID2fGySiuYNNzKtjfGy44p5RGVcMpTYJQZSbFj1hbec8NoL9B4dkEuj30PKf5cXJ71PuR1HTO5uGStSosWtwoLSY9kuSrn5Lw-pFAuedAIejWoB70a1KtBDVwXgyX08tR-6fau_xP5rawAr06AydaMPpnJhvyXa6kCVLJwb46cKzLug0s62-Am6_qQnJ11H8P_93j7T9yOYQpl4p17cHmIS5qKZo06Uw36y_rr9dWIAC1FwX4BPviiDg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>911951791</pqid></control><display><type>article</type><title>Circulating microRNA-21 as a novel biomarker for hepatocellular carcinoma</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Tomimaru, Yoshito ; Eguchi, Hidetoshi ; Nagano, Hiroaki ; Wada, Hiroshi ; Kobayashi, Shogo ; Marubashi, Shigeru ; Tanemura, Masahiro ; Tomokuni, Akira ; Takemasa, Ichiro ; Umeshita, Koji ; Kanto, Tatsuya ; Doki, Yuichiro ; Mori, Masaki</creator><creatorcontrib>Tomimaru, Yoshito ; Eguchi, Hidetoshi ; Nagano, Hiroaki ; Wada, Hiroshi ; Kobayashi, Shogo ; Marubashi, Shigeru ; Tanemura, Masahiro ; Tomokuni, Akira ; Takemasa, Ichiro ; Umeshita, Koji ; Kanto, Tatsuya ; Doki, Yuichiro ; Mori, Masaki</creatorcontrib><description>Background & Aims Several groups have reported the significance of circulating microRNA as a biochemical marker of cancer. To our knowledge, however, there are no reports on the significance of circulating microRNA in hepatocellular carcinoma. The aim of this study was to evaluate the significance of plasma microRNA-21 level as a biochemical marker for hepatocellular carcinoma. Methods Plasma microRNA-21 level was measured by qRT-PCR in 10 patients before and after curative resection of hepatocellular carcinoma. Plasma microRNA-21 was also compared in other groups of: 126 patients with hepatocellular carcinoma, 30 patients with chronic hepatitis, and 50 healthy volunteers. The power of microRNA-21 in differentiating hepatocellular carcinoma from chronic hepatitis or from healthy volunteers was compared to that of α-fetoprotein. Results In the 10-patient group, plasma microRNA-21 levels significantly diminished after surgery compared with the pre-operative values ( p = 0.0125). Plasma microRNA-21 level in the 126 patients with hepatocellular carcinoma was significantly higher than in patients with chronic hepatitis and healthy volunteers ( p < 0.0001 , p < 0.0001, respectively). ROC analysis of plasma microRNA-21 yielded an AUC of 0.773 with 61.1% sensitivity and 83.3% specificity when differentiating hepatocellular carcinoma from chronic hepatitis, and an AUC of 0.953 with 87.3% sensitivity and 92.0% specificity when differentiating hepatocellular carcinoma from healthy volunteers. Both sets of values were superior to α-fetoprotein and improved for the combination of microRNA-21 and α-fetoprotein. Conclusions Plasma microRNA-21 level is a promising biochemical marker for hepatocellular carcinoma.</description><identifier>ISSN: 0168-8278</identifier><identifier>EISSN: 1600-0641</identifier><identifier>DOI: 10.1016/j.jhep.2011.04.026</identifier><identifier>PMID: 21749846</identifier><identifier>CODEN: JOHEEC</identifier><language>eng</language><publisher>Kidlington: Elsevier B.V</publisher><subject>Aged ; alpha-Fetoproteins - metabolism ; Biological and medical sciences ; Biomarker ; Biomarkers, Tumor - blood ; Biomarkers, Tumor - genetics ; Carcinoma, Hepatocellular - blood ; Carcinoma, Hepatocellular - complications ; Carcinoma, Hepatocellular - genetics ; Carcinoma, Hepatocellular - surgery ; Case-Control Studies ; Female ; Gastroenterology and Hepatology ; Gastroenterology. Liver. Pancreas. Abdomen ; Hepatitis B, Chronic - blood ; Hepatitis B, Chronic - complications ; Hepatitis B, Chronic - genetics ; Hepatitis C, Chronic - blood ; Hepatitis C, Chronic - complications ; Hepatitis C, Chronic - genetics ; Hepatocellular carcinoma ; Humans ; Liver - metabolism ; Liver Neoplasms - blood ; Liver Neoplasms - complications ; Liver Neoplasms - genetics ; Liver Neoplasms - surgery ; Liver. Biliary tract. Portal circulation. Exocrine pancreas ; Male ; Medical sciences ; microRNA ; microRNA-21 ; MicroRNAs - blood ; MicroRNAs - genetics ; MicroRNAs - metabolism ; Middle Aged ; Plasma ; Prognosis ; Tumors</subject><ispartof>Journal of hepatology, 2012-01, Vol.56 (1), p.167-175</ispartof><rights>European Association for the Study of the Liver</rights><rights>2011 European Association for the Study of the Liver</rights><rights>2015 INIST-CNRS</rights><rights>Copyright © 2011 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c506t-b451308b43095638a4c85daaf8b399f1196e9f20323a821b3cc130f4a32d61af3</citedby><cites>FETCH-LOGICAL-c506t-b451308b43095638a4c85daaf8b399f1196e9f20323a821b3cc130f4a32d61af3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0168827811005216$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=25290198$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21749846$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Tomimaru, Yoshito</creatorcontrib><creatorcontrib>Eguchi, Hidetoshi</creatorcontrib><creatorcontrib>Nagano, Hiroaki</creatorcontrib><creatorcontrib>Wada, Hiroshi</creatorcontrib><creatorcontrib>Kobayashi, Shogo</creatorcontrib><creatorcontrib>Marubashi, Shigeru</creatorcontrib><creatorcontrib>Tanemura, Masahiro</creatorcontrib><creatorcontrib>Tomokuni, Akira</creatorcontrib><creatorcontrib>Takemasa, Ichiro</creatorcontrib><creatorcontrib>Umeshita, Koji</creatorcontrib><creatorcontrib>Kanto, Tatsuya</creatorcontrib><creatorcontrib>Doki, Yuichiro</creatorcontrib><creatorcontrib>Mori, Masaki</creatorcontrib><title>Circulating microRNA-21 as a novel biomarker for hepatocellular carcinoma</title><title>Journal of hepatology</title><addtitle>J Hepatol</addtitle><description>Background & Aims Several groups have reported the significance of circulating microRNA as a biochemical marker of cancer. To our knowledge, however, there are no reports on the significance of circulating microRNA in hepatocellular carcinoma. The aim of this study was to evaluate the significance of plasma microRNA-21 level as a biochemical marker for hepatocellular carcinoma. Methods Plasma microRNA-21 level was measured by qRT-PCR in 10 patients before and after curative resection of hepatocellular carcinoma. Plasma microRNA-21 was also compared in other groups of: 126 patients with hepatocellular carcinoma, 30 patients with chronic hepatitis, and 50 healthy volunteers. The power of microRNA-21 in differentiating hepatocellular carcinoma from chronic hepatitis or from healthy volunteers was compared to that of α-fetoprotein. Results In the 10-patient group, plasma microRNA-21 levels significantly diminished after surgery compared with the pre-operative values ( p = 0.0125). Plasma microRNA-21 level in the 126 patients with hepatocellular carcinoma was significantly higher than in patients with chronic hepatitis and healthy volunteers ( p < 0.0001 , p < 0.0001, respectively). ROC analysis of plasma microRNA-21 yielded an AUC of 0.773 with 61.1% sensitivity and 83.3% specificity when differentiating hepatocellular carcinoma from chronic hepatitis, and an AUC of 0.953 with 87.3% sensitivity and 92.0% specificity when differentiating hepatocellular carcinoma from healthy volunteers. Both sets of values were superior to α-fetoprotein and improved for the combination of microRNA-21 and α-fetoprotein. Conclusions Plasma microRNA-21 level is a promising biochemical marker for hepatocellular carcinoma.</description><subject>Aged</subject><subject>alpha-Fetoproteins - metabolism</subject><subject>Biological and medical sciences</subject><subject>Biomarker</subject><subject>Biomarkers, Tumor - blood</subject><subject>Biomarkers, Tumor - genetics</subject><subject>Carcinoma, Hepatocellular - blood</subject><subject>Carcinoma, Hepatocellular - complications</subject><subject>Carcinoma, Hepatocellular - genetics</subject><subject>Carcinoma, Hepatocellular - surgery</subject><subject>Case-Control Studies</subject><subject>Female</subject><subject>Gastroenterology and Hepatology</subject><subject>Gastroenterology. Liver. Pancreas. Abdomen</subject><subject>Hepatitis B, Chronic - blood</subject><subject>Hepatitis B, Chronic - complications</subject><subject>Hepatitis B, Chronic - genetics</subject><subject>Hepatitis C, Chronic - blood</subject><subject>Hepatitis C, Chronic - complications</subject><subject>Hepatitis C, Chronic - genetics</subject><subject>Hepatocellular carcinoma</subject><subject>Humans</subject><subject>Liver - metabolism</subject><subject>Liver Neoplasms - blood</subject><subject>Liver Neoplasms - complications</subject><subject>Liver Neoplasms - genetics</subject><subject>Liver Neoplasms - surgery</subject><subject>Liver. Biliary tract. Portal circulation. Exocrine pancreas</subject><subject>Male</subject><subject>Medical sciences</subject><subject>microRNA</subject><subject>microRNA-21</subject><subject>MicroRNAs - blood</subject><subject>MicroRNAs - genetics</subject><subject>MicroRNAs - metabolism</subject><subject>Middle Aged</subject><subject>Plasma</subject><subject>Prognosis</subject><subject>Tumors</subject><issn>0168-8278</issn><issn>1600-0641</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kU1v1DAQhi0EotvCH-CAckE9JczYjteWEFK1olCpAomPs-U4NjjNxoudVOq_x9EuIHHgNJfnnY9nCHmB0CCgeD00ww93aCggNsAboOIR2aAAqEFwfEw2BZK1pFt5Rs5zHgCAgeJPyRnFLVeSiw252YVkl9HMYfpe7YNN8fPHq5piZXJlqineu7HqQtybdOdS5WOqykgzR-vGscRSZU2yYSrAM_LEmzG756d6Qb5dv_u6-1Dffnp_s7u6rW0LYq473iID2fGySiuYNNzKtjfGy44p5RGVcMpTYJQZSbFj1hbec8NoL9B4dkEuj30PKf5cXJ71PuR1HTO5uGStSosWtwoLSY9kuSrn5Lw-pFAuedAIejWoB70a1KtBDVwXgyX08tR-6fau_xP5rawAr06AydaMPpnJhvyXa6kCVLJwb46cKzLug0s62-Am6_qQnJ11H8P_93j7T9yOYQpl4p17cHmIS5qKZo06Uw36y_rr9dWIAC1FwX4BPviiDg</recordid><startdate>20120101</startdate><enddate>20120101</enddate><creator>Tomimaru, Yoshito</creator><creator>Eguchi, Hidetoshi</creator><creator>Nagano, Hiroaki</creator><creator>Wada, Hiroshi</creator><creator>Kobayashi, Shogo</creator><creator>Marubashi, Shigeru</creator><creator>Tanemura, Masahiro</creator><creator>Tomokuni, Akira</creator><creator>Takemasa, Ichiro</creator><creator>Umeshita, Koji</creator><creator>Kanto, Tatsuya</creator><creator>Doki, Yuichiro</creator><creator>Mori, Masaki</creator><general>Elsevier B.V</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20120101</creationdate><title>Circulating microRNA-21 as a novel biomarker for hepatocellular carcinoma</title><author>Tomimaru, Yoshito ; Eguchi, Hidetoshi ; Nagano, Hiroaki ; Wada, Hiroshi ; Kobayashi, Shogo ; Marubashi, Shigeru ; Tanemura, Masahiro ; Tomokuni, Akira ; Takemasa, Ichiro ; Umeshita, Koji ; Kanto, Tatsuya ; Doki, Yuichiro ; Mori, Masaki</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c506t-b451308b43095638a4c85daaf8b399f1196e9f20323a821b3cc130f4a32d61af3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Aged</topic><topic>alpha-Fetoproteins - metabolism</topic><topic>Biological and medical sciences</topic><topic>Biomarker</topic><topic>Biomarkers, Tumor - blood</topic><topic>Biomarkers, Tumor - genetics</topic><topic>Carcinoma, Hepatocellular - blood</topic><topic>Carcinoma, Hepatocellular - complications</topic><topic>Carcinoma, Hepatocellular - genetics</topic><topic>Carcinoma, Hepatocellular - surgery</topic><topic>Case-Control Studies</topic><topic>Female</topic><topic>Gastroenterology and Hepatology</topic><topic>Gastroenterology. Liver. Pancreas. Abdomen</topic><topic>Hepatitis B, Chronic - blood</topic><topic>Hepatitis B, Chronic - complications</topic><topic>Hepatitis B, Chronic - genetics</topic><topic>Hepatitis C, Chronic - blood</topic><topic>Hepatitis C, Chronic - complications</topic><topic>Hepatitis C, Chronic - genetics</topic><topic>Hepatocellular carcinoma</topic><topic>Humans</topic><topic>Liver - metabolism</topic><topic>Liver Neoplasms - blood</topic><topic>Liver Neoplasms - complications</topic><topic>Liver Neoplasms - genetics</topic><topic>Liver Neoplasms - surgery</topic><topic>Liver. Biliary tract. Portal circulation. Exocrine pancreas</topic><topic>Male</topic><topic>Medical sciences</topic><topic>microRNA</topic><topic>microRNA-21</topic><topic>MicroRNAs - blood</topic><topic>MicroRNAs - genetics</topic><topic>MicroRNAs - metabolism</topic><topic>Middle Aged</topic><topic>Plasma</topic><topic>Prognosis</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tomimaru, Yoshito</creatorcontrib><creatorcontrib>Eguchi, Hidetoshi</creatorcontrib><creatorcontrib>Nagano, Hiroaki</creatorcontrib><creatorcontrib>Wada, Hiroshi</creatorcontrib><creatorcontrib>Kobayashi, Shogo</creatorcontrib><creatorcontrib>Marubashi, Shigeru</creatorcontrib><creatorcontrib>Tanemura, Masahiro</creatorcontrib><creatorcontrib>Tomokuni, Akira</creatorcontrib><creatorcontrib>Takemasa, Ichiro</creatorcontrib><creatorcontrib>Umeshita, Koji</creatorcontrib><creatorcontrib>Kanto, Tatsuya</creatorcontrib><creatorcontrib>Doki, Yuichiro</creatorcontrib><creatorcontrib>Mori, Masaki</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of hepatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tomimaru, Yoshito</au><au>Eguchi, Hidetoshi</au><au>Nagano, Hiroaki</au><au>Wada, Hiroshi</au><au>Kobayashi, Shogo</au><au>Marubashi, Shigeru</au><au>Tanemura, Masahiro</au><au>Tomokuni, Akira</au><au>Takemasa, Ichiro</au><au>Umeshita, Koji</au><au>Kanto, Tatsuya</au><au>Doki, Yuichiro</au><au>Mori, Masaki</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Circulating microRNA-21 as a novel biomarker for hepatocellular carcinoma</atitle><jtitle>Journal of hepatology</jtitle><addtitle>J Hepatol</addtitle><date>2012-01-01</date><risdate>2012</risdate><volume>56</volume><issue>1</issue><spage>167</spage><epage>175</epage><pages>167-175</pages><issn>0168-8278</issn><eissn>1600-0641</eissn><coden>JOHEEC</coden><abstract>Background & Aims Several groups have reported the significance of circulating microRNA as a biochemical marker of cancer. To our knowledge, however, there are no reports on the significance of circulating microRNA in hepatocellular carcinoma. The aim of this study was to evaluate the significance of plasma microRNA-21 level as a biochemical marker for hepatocellular carcinoma. Methods Plasma microRNA-21 level was measured by qRT-PCR in 10 patients before and after curative resection of hepatocellular carcinoma. Plasma microRNA-21 was also compared in other groups of: 126 patients with hepatocellular carcinoma, 30 patients with chronic hepatitis, and 50 healthy volunteers. The power of microRNA-21 in differentiating hepatocellular carcinoma from chronic hepatitis or from healthy volunteers was compared to that of α-fetoprotein. Results In the 10-patient group, plasma microRNA-21 levels significantly diminished after surgery compared with the pre-operative values ( p = 0.0125). Plasma microRNA-21 level in the 126 patients with hepatocellular carcinoma was significantly higher than in patients with chronic hepatitis and healthy volunteers ( p < 0.0001 , p < 0.0001, respectively). ROC analysis of plasma microRNA-21 yielded an AUC of 0.773 with 61.1% sensitivity and 83.3% specificity when differentiating hepatocellular carcinoma from chronic hepatitis, and an AUC of 0.953 with 87.3% sensitivity and 92.0% specificity when differentiating hepatocellular carcinoma from healthy volunteers. Both sets of values were superior to α-fetoprotein and improved for the combination of microRNA-21 and α-fetoprotein. Conclusions Plasma microRNA-21 level is a promising biochemical marker for hepatocellular carcinoma.</abstract><cop>Kidlington</cop><pub>Elsevier B.V</pub><pmid>21749846</pmid><doi>10.1016/j.jhep.2011.04.026</doi><tpages>9</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0168-8278 |
| ispartof | Journal of hepatology, 2012-01, Vol.56 (1), p.167-175 |
| issn | 0168-8278 1600-0641 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_911951791 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Aged alpha-Fetoproteins - metabolism Biological and medical sciences Biomarker Biomarkers, Tumor - blood Biomarkers, Tumor - genetics Carcinoma, Hepatocellular - blood Carcinoma, Hepatocellular - complications Carcinoma, Hepatocellular - genetics Carcinoma, Hepatocellular - surgery Case-Control Studies Female Gastroenterology and Hepatology Gastroenterology. Liver. Pancreas. Abdomen Hepatitis B, Chronic - blood Hepatitis B, Chronic - complications Hepatitis B, Chronic - genetics Hepatitis C, Chronic - blood Hepatitis C, Chronic - complications Hepatitis C, Chronic - genetics Hepatocellular carcinoma Humans Liver - metabolism Liver Neoplasms - blood Liver Neoplasms - complications Liver Neoplasms - genetics Liver Neoplasms - surgery Liver. Biliary tract. Portal circulation. Exocrine pancreas Male Medical sciences microRNA microRNA-21 MicroRNAs - blood MicroRNAs - genetics MicroRNAs - metabolism Middle Aged Plasma Prognosis Tumors |
| title | Circulating microRNA-21 as a novel biomarker for hepatocellular carcinoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T11%3A33%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Circulating%20microRNA-21%20as%20a%20novel%20biomarker%20for%20hepatocellular%20carcinoma&rft.jtitle=Journal%20of%20hepatology&rft.au=Tomimaru,%20Yoshito&rft.date=2012-01-01&rft.volume=56&rft.issue=1&rft.spage=167&rft.epage=175&rft.pages=167-175&rft.issn=0168-8278&rft.eissn=1600-0641&rft.coden=JOHEEC&rft_id=info:doi/10.1016/j.jhep.2011.04.026&rft_dat=%3Cproquest_cross%3E911951791%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=911951791&rft_id=info:pmid/21749846&rft_els_id=S0168827811005216&rfr_iscdi=true |